Autonomix Medical (AMIX) said Monday three patients responded to radio frequency pain management with femoral access in an ongoing clinical trial evaluating its potential to manage pain in pancreatic cancer patients without the use of opioids.
Two patients in the same group, but treated with brachial access, didn't show improvement in their pain scores, or worsened, the company said, but all paitents treated with the technology were able to eliminate their opioid use at four to six weeks post-procedure.
The company said the preliminary results came from the first five "lead-in" patients in its ongoing proof-of-concept human trial assessing the delivery of transvascular energy to ablate problematic nerves and mitigate pain in pancreatic cancer pain patients.
The trial is expected to finish enrolment by yearend, the company said.
The company's technology platform uses a catheter-based microchip sensing array antenae that can detect neural signals. Once target nerves are identified, the treatment uses radio frequency ablation technology to kill targeted nerves, the company said.
Autonomix shares soared more than 150% in recent Monday premarket activity.
Price: 19.59, Change: +11.88, Percent Change: +154.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。